Early ravulizumab for severe myasthenia gravis crisis in the ICU
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have generalized myasthenia gravis confirmed by a positive blood test for acetylcholine receptor antibodies.
- You have already received more than one round of plasma exchange or IVIg for this crisis.
- You are in the intensive care unit with very severe muscle weakness (class IV or V).
- You are willing to follow the study plan, including getting vaccinated against meningitis.
- You do not have a thymoma or any active cancer or serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
This study looks at protein changes in patients with myasthenia gravis who are taking the medication Ravulizumab. By understanding these changes, researchers hope to learn more about the condition and how the treatment works.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.